CTOs on the Move

Candel Therapeutics

www.candeltx.com

 
Also known as Advantagene. Inc., we are a Massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our Gene Mediated Cytotoxic (GMCI™) platform and our rQNestin34.5 platform. GMCI™ is an "off-the-shelf"​ immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.candeltx.com
  • 117 Kendrick Street Suite 450
    Needham, MA USA 02494
  • Phone: 617.916.5445

Executives

Name Title Contact Details
Seshu Tyagarajan
Chief Technical and Development Officer Profile

Funding

Candel Therapeutics raised $22.5M on 04/01/2019
Candel Therapeutics raised $25M on 03/01/2022

Similar Companies

Solugen

Solugen is a venture-backed biotech startup that replaces petroleum based products with plant-derived substitutes.

West Virginia Biometrics Initiative

West Virginia Biometrics Initiative is a Charleston, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MustGrow Biologics

An #AG biotech company focused on providing natural, science-based biological solutions for high-value crops. CSE: MGRO | OTCQB: MGROF | FRA: 0C0

Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.

Curemark

Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark`s pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson`s disease.